Squibb

In September 2024, Bristol Myers Squibb (BMS) introduced Cobenfy (xanomeline and trospium chloride), a groundbreaking oral medication for schizophrenia. Unlike

Vitamin B complex supplements have become an essential part of many people’s daily health routines, providing a combination of vitamins